DiaSorin S.p.A. (IT:DIA)
:DIA
Want to see IT:DIA full AI Analyst Report?
Top Page
DiaSorin S.p.A.
(DIA)
Select Model
Select Model
Rating:56Neutral
Price Target:
€64.00
▲(4.75% Upside)
Action:ReiteratedDate:04/05/26
The score is driven mainly by solid profitability and cash generation, but is held back by weakening recent momentum in revenue, margins and free cash flow. Technicals are notably weak with the stock trading below major moving averages and a negative MACD, while valuation is only moderately supported by the dividend given a ~25.6 P/E.
Positive Factors
High gross and EBIT margins
Sustained 2025 gross margin (~65%) and EBIT margin (~19%) indicate durable pricing power and efficient core operations in immuno/molecular diagnostics. High structural margins support reinvestment in assays, instrument R&D, and buffer against cyclical demand swings, reinforcing long-term profitability.
Negative Factors
Stagnant/declining revenue trend
Flat to slightly down revenue in 2024–2025 following a larger 2023 decline signals weakening top-line momentum. For a consumables-driven diagnostics firm, prolonged stagnant sales limit installed-base growth and assay adoption, constraining long-term organic revenue expansion and the ability to leverage fixed costs into higher profits.
Read all positive and negative factors
Positive Factors
Negative Factors
High gross and EBIT margins
Sustained 2025 gross margin (~65%) and EBIT margin (~19%) indicate durable pricing power and efficient core operations in immuno/molecular diagnostics. High structural margins support reinvestment in assays, instrument R&D, and buffer against cyclical demand swings, reinforcing long-term profitability.
Read all positive factors
DiaSorin S.p.A. (DIA) vs. iShares MSCI Italy ETF (EWI)
Market Cap
€3.13B
Dividend Yield1.8%
Average Volume (3M)221.33K
Price to Earnings (P/E)25.6
Beta (1Y)0.39
Revenue Growth0.81%
EPS Growth-15.40%
CountryIT
Employees3,249
SectorGeneral
Sector StrengthN/A
IndustryMedical - Diagnostics & Research
Share Statistics
EPS (TTM)0.89
Shares Outstanding55,948,257
10 Day Avg. Volume225,158
30 Day Avg. Volume221,334
Financial Highlights & Ratios
PEG Ratio-1.25
Price to Book (P/B)2.42
Price to Sales (P/S)3.21
P/FCF Ratio18.72
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€65.75Price Target Upside7.61% Upside
Rating ConsensusHold
Number of Analyst Covering4
EPS Forecast (FY)3.95
Revenue Forecast (FY)€1.23B
DiaSorin S.p.A. Business Overview & Revenue Model
Company Description
DiaSorin S.p.A. develops, manufactures, and distributes immunodiagnostics and molecular diagnostics testing kits in Europe, Africa, North America, Central and South America, the Asia Pacific, and China. The company provides various immunodiagnosti...
How the Company Makes Money
DiaSorin primarily makes money by selling in vitro diagnostic testing solutions to clinical laboratories and other healthcare customers. Its core revenue stream is recurring sales of reagents, test kits, and other consumables used to run assays on...
DiaSorin S.p.A. Financial Statement Overview
Summary
Income Statement
66
Positive
Balance Sheet
58
Neutral
Cash Flow
60
Neutral
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 1.20B | 1.19B | 1.15B | 1.36B | 1.24B |
| Gross Profit | 773.00M | 781.00M | 741.19M | 900.61M | 824.77M |
| EBITDA | 228.00M | 399.04M | 333.40M | 479.71M | 504.56M |
| Net Income | 150.00M | 188.10M | 159.85M | 240.91M | 310.97M |
Balance Sheet | |||||
| Total Assets | 2.87B | 3.30B | 3.21B | 3.41B | 3.23B |
| Cash, Cash Equivalents and Short-Term Investments | 211.65M | 378.92M | 403.39M | 413.22M | 403.02M |
| Total Debt | 791.16M | 1.01B | 1.19B | 1.35B | 1.40B |
| Total Liabilities | 1.30B | 1.51B | 1.67B | 1.89B | 1.86B |
| Stockholders Equity | 1.58B | 1.80B | 1.54B | 1.52B | 1.37B |
Cash Flow | |||||
| Free Cash Flow | 205.08M | 239.07M | 266.20M | 275.65M | 283.29M |
| Operating Cash Flow | 342.76M | 358.78M | 311.66M | 389.34M | 400.66M |
| Investing Cash Flow | -144.52M | -49.81M | -29.10M | -231.95M | -1.61B |
| Financing Cash Flow | -351.18M | -259.13M | -235.96M | -333.04M | 1.26B |
DiaSorin S.p.A. Technical Analysis
Neutral
61.10
Price Trends
66.10
Negative
66.84
Negative
73.52
Negative
Market Momentum
-0.82
Negative
51.72
Neutral
84.63
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IT:DIA, the sentiment is Neutral. The current price of 61.1 is above the 20-day moving average (MA) of 60.76, below the 50-day MA of 66.10, and below the 200-day MA of 73.52, indicating a neutral trend. The MACD of -0.82 indicates Negative momentum. The RSI at 51.72 is Neutral, neither overbought nor oversold. The STOCH value of 84.63 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for IT:DIA.
DiaSorin S.p.A. Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
75 Outperform | €10.24B | 22.48 | 21.26% | 2.67% | 11.82% | 6.87% | |
62 Neutral | €665.16M | 29.60 | 11.48% | ― | -0.99% | 118.45% | |
61 Neutral | €1.05B | 10.94 | 15.29% | 1.58% | 4.42% | -16.04% | |
56 Neutral | €3.13B | 25.59 | 12.16% | 1.80% | 0.81% | -15.40% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
47 Neutral | €2.11B | 34.09 | 8.86% | 2.13% | -0.56% | -36.55% | |
41 Neutral | €682.41K | -6.36 | -51.46% | ― | -27.40% | 82.08% |
* General Sector Average
IT:DIA
DiaSorin S.p.A.
58.02
-41.41
-41.65%
IT:AMP
Amplifon S.p.A.
9.40
-7.79
-45.32%
IT:ELN
El.En. S.p.A.
13.09
4.18
46.95%
IT:FDA
Fidia Spa
0.01
-0.51
-98.08%
IT:REC
Recordati Industria Chimica e Farmaceutica SPA
49.64
-2.17
-4.18%
IT:SFL
Safilo Group SpA
1.60
0.86
115.92%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.